Regardless of the ER, PR, and HER2 status or the use of the HER2-targeted trastuzumab drug, the high count of M2 CD163+ TAM was associated with a poor outcome in HER2+ breast cancer patients [73]. Here, ERBB2 is linked to breast carcinoma.